Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era Authors: Nadia Harbeck, MD, PhD; Frédérique Penault-Llorca, MD; Giampaolo Bianchini, MD; Henry Cain, MBChB, FRCS, MD; Janice Walshe, MB BCh, BAO, MRCPI

https://www.medscape.org/viewarticle/refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261111-OUS-HONC-refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl-cta